- Bioactive Compounds
- By Signaling Pathways
- PI3K/Akt/mTOR
- Epigenetics
- Methylation
- Immunology & Inflammation
- Protein Tyrosine Kinase
- Angiogenesis
- Apoptosis
- Autophagy
- ER stress & UPR
- JAK/STAT
- MAPK
- Cytoskeletal Signaling
- Cell Cycle
- TGF-beta/Smad
- Compound Libraries
- Antibodies
- Bioreagents
- qPCR
- 2x SYBR Green qPCR Master Mix
- 2x SYBR Green qPCR Master Mix(Low ROX)
- 2x SYBR Green qPCR Master Mix(High ROX)
- Protein Assay
- Protein A/G Magnetic Beads for IP
- Anti-DYKDDDDK Tag magnetic beads
- Anti-DYKDDDDK Tag Affinity Gel
- Anti-Myc magnetic beads
- Anti-HA magnetic beads
- Poly DYKDDDDK Tag Peptide lyophilized powder
- Protease Inhibitor Cocktail
- Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO)
- Phosphatase Inhibitor Cocktail (2 Tubes, 100X)
- Cell Biology
- Cell Counting Kit-8 (CCK-8)
- Animal Experiment
- Mouse Direct PCR Kit (For Genotyping)
- New Products
- Contact Us
-
Australia
-
Austria
-
Belgium
-
Brazil
-
Canada
-
China
-
Czech Republic
-
Denmark
-
Finland
-
France
-
Germany
-
Greece
-
Hong Kong
-
Hungary
-
Iceland
-
India
-
Ireland
-
Israel
-
Italy
-
Japan
-
Korea
-
Luxembourg
-
Malaysia
-
Netherlands
-
New Zealand
-
Norway
-
Poland
-
Qatar
-
Romania
-
Saudi Arabia
-
Singapore
-
Spain
-
Sweden
-
Switzerland
-
Taiwan
-
Turkey
-
United Kingdom
-
United States
-
Other Countries
IL Receptor
IL Receptor Products
- All (20)
- IL Receptor Inhibitors (4)
- IL Receptor Antibodies (14)
- IL Receptor Modulators (2)
- New IL Receptor Products
| Catalog No. | Product Name | Information | Product Use Citations | Product Validations |
|---|---|---|---|---|
| S1322 | Dexamethasone | Dexamethasone is a potent synthetic member of the glucocorticoid class of steroid drugs, and an interleukin receptor modulator that has anti-inflammatory and immunosuppressant effects. Dexamethasone induces autophagy and mitophagy. Dexamethasone is tested in hospitalized patients with COVID-19 and is found to have benefits for critically ill patients. |
|
|
| A2012 | Tocilizumab (anti-IL-6R) | Tocilizumab (anti-IL-6R) is a humanized monoclonal antibody that binds to the interleukin-6 receptor, MW: 148 KD. | ||
| S3124 | Dexamethasone Acetate | Dexamethasone (NSC 39471,Dexamethasone 21-acetate) is a potent synthetic member of the glucocorticoid class of steroid drugs, and an interleukin receptor modulator that has anti-inflammatory and immunosuppressant effects. |
|
|
| S4028 | Dexamethasone Sodium Phosphate | Dexamethasone (Dexamethasone 21-phosphate disodium salt) is a potent synthetic member of the glucocorticoid class of steroid drugs, and an interleukin receptor modulator that has anti-inflammatory and immunosuppressant effects. |
|
|
| A2011 | Sarilumab (anti-IL-6Rα) | Sarilumab (anti-IL-6Rα) is a fully human anti-IL-6Rα mAb that binds membrane-bound and soluble human IL-6Rα with high affinity, MW: 144.13 KD. | ||
| S8562 | IRAK4-IN-2 | IRAK4-IN-2 is a reversible kinase inhibitor that modulates IRAK4 function in both the toll-like receptor (TLR) and interleukin 1 receptor (IL-1R) signaling cascades. | ||
| S5764 | YM 90709 | YM 90709 is a novel IL-5 inhibitor which selectively blocks the binding of IL-5 to the IL-5 receptor (IL-5R). | ||
| A2424 | Anti-IL-7Ra / CD127 | Anti-IL-7Ra / CD127 is a monoclonal antibody against human IL-7Rα with therapeutic benefit against T-ALL (T-cell acute lymphoblastic leukemia). MW: 145.5 kD. | ||
| A2427 | Benralizumab (Anti-IL-5Ra/ CD125) | Benralizumab (Anti-IL-5Ra/ CD125) is an afucosylated, humanized monoclonal antibody against the alpha chain of the interleukin-5 receptor (IL-5Ra) with potential anti-asthmatic activity. MW: 145.5 kD. | ||
| A2431 | Talacotuzumab (Anti-IL-3Ra / CD123) | Talacotuzumab (Anti-IL-3Ra / CD123) is a humanized IgG1 monoclonal antibody against CD123 (Interleukin-3 receptor alpha chain or IL3RA) with potential antineoplastic activity. MW: 146.06 kD. | ||
| A2433 | Nemolizumab (Anti-IL-31Ra) | Nemolizumab (Anti-IL-31Ra) is a humanized monoclonal antibody, targeting IL-31Ra. It inhibits the binding of interleukin-31 (IL-31) to its receptor and subsequent signal transduction. Nemolizumab can used be in research of atopic dermatitis (AD). MW:145.5 KD. | ||
| A2631 | Anti-IL-3Ra / CD123 (SGN-CD123A) | Anti-IL-3Ra / CD123 (SGN-CD123A) is an antibody-drug conjugate targeting IL-3 alpha chain receptor (CD123). It is a potent antileukemic agent in treatment of acute myelogenous leukemia(AML). MW :146.14 KD. | ||
| E3310 | Brassica Juncea Seed Extract | Brassica juncea seed Extract is obtained from seeds of Brassica juncea L., which confers a protective/therapeutic effect against thioacetamide-induced acute liver failure in experimental animal models, by markedly downregulating the expression levels of TNF-α and IL-6, and reversing DNA genotoxicity. | ||
| A2665 | Anrukinzumab (Anti-IL-13) | Anrukinzumab (Anti-IL-13) is a humanized monoclonal antibody targeting IL-13. It reduces lung inflammation and can be used in studies of ulcerative colitis (UC) as well as asthma. MW :150 KD. | ||
| A2666 | Anti-IL-13Ra2 / CD213a2 | Anti-IL-13Ra2 / CD213a2 is a humanized monoclonal antibody targeting IL-13Ra2. It exhibits potentcy against malignant gliomas (MG), head and neck tumors, ovarian cancer and kidney cancer. MW :150 KD. | ||
| A2667 | Imsidolimab (Anti-IL-1RL2 / IL-36R) | Imsidolimab (Anti-IL-1RL2 / IL-36R) is a high-affinity, humanized monoclonal antibody targeting IL-36R. It has potential application in generalized pustular psoriasis (GPP) and other inflammatory skin diseases. MW :150 KD. | ||
| A2668 | Etokimab (Anti-IL-33) | Etokimab (Anti-IL-33) is a humanized monoclonal antibody that targets IL-33. It can be used for the research of atopic dermatitis. MW :146.56 KD. | ||
| A2669 | Lusvertikimab (Anti-IL-7Ra / CD127) | Lusvertikimab (Anti-IL-7Ra / CD127) is a humanized monoclonal antibody targeting IL7R. It has anti-leukemic efficacy and has the potential for B cell precursor acute lymphoblastic leukemia (BCP-ALL) research. MW :145.64 KD. | ||
| A2107 | Anti-mouse CD25 (IL-2Rα)-InVivo | The PC-61.5.3 monoclonal antibody reacts with mouse IL-2Rα also known as CD25, Ly-43, p55, or Tac.The PC-61.5.3 antibody has been shown to inhibit the binding of IL-2 to both the low and high affinity IL-2 receptor forms. Additionally, the PC-61.5.3 antibody is commonly used to deplete CD4+FoxP3+ T regulatory cells in vivo. |
-InVivo.gif)
|
|
| A2109 | Anti-mouse IL-4-InVivo | The 11B11 monoclonal antibody reacts with mouse IL-4 (interleukin-4) which is a multifunctional 14 kDa cytokine.The 11B11 monoclonal antibody has been shown to neutralize the bioactivity of natural or recombinant IL-4. | ||
| S4028 | Dexamethasone Sodium Phosphate | Dexamethasone (Dexamethasone 21-phosphate disodium salt) is a potent synthetic member of the glucocorticoid class of steroid drugs, and an interleukin receptor modulator that has anti-inflammatory and immunosuppressant effects. |
|
|
| S8562 | IRAK4-IN-2 | IRAK4-IN-2 is a reversible kinase inhibitor that modulates IRAK4 function in both the toll-like receptor (TLR) and interleukin 1 receptor (IL-1R) signaling cascades. | ||
| S5764 | YM 90709 | YM 90709 is a novel IL-5 inhibitor which selectively blocks the binding of IL-5 to the IL-5 receptor (IL-5R). | ||
| E3310 | Brassica Juncea Seed Extract | Brassica juncea seed Extract is obtained from seeds of Brassica juncea L., which confers a protective/therapeutic effect against thioacetamide-induced acute liver failure in experimental animal models, by markedly downregulating the expression levels of TNF-α and IL-6, and reversing DNA genotoxicity. | ||
| A2012 | Tocilizumab (anti-IL-6R) | Tocilizumab (anti-IL-6R) is a humanized monoclonal antibody that binds to the interleukin-6 receptor, MW: 148 KD. | ||
| A2011 | Sarilumab (anti-IL-6Rα) | Sarilumab (anti-IL-6Rα) is a fully human anti-IL-6Rα mAb that binds membrane-bound and soluble human IL-6Rα with high affinity, MW: 144.13 KD. | ||
| A2424 | Anti-IL-7Ra / CD127 | Anti-IL-7Ra / CD127 is a monoclonal antibody against human IL-7Rα with therapeutic benefit against T-ALL (T-cell acute lymphoblastic leukemia). MW: 145.5 kD. | ||
| A2427 | Benralizumab (Anti-IL-5Ra/ CD125) | Benralizumab (Anti-IL-5Ra/ CD125) is an afucosylated, humanized monoclonal antibody against the alpha chain of the interleukin-5 receptor (IL-5Ra) with potential anti-asthmatic activity. MW: 145.5 kD. | ||
| A2431 | Talacotuzumab (Anti-IL-3Ra / CD123) | Talacotuzumab (Anti-IL-3Ra / CD123) is a humanized IgG1 monoclonal antibody against CD123 (Interleukin-3 receptor alpha chain or IL3RA) with potential antineoplastic activity. MW: 146.06 kD. | ||
| A2433 | Nemolizumab (Anti-IL-31Ra) | Nemolizumab (Anti-IL-31Ra) is a humanized monoclonal antibody, targeting IL-31Ra. It inhibits the binding of interleukin-31 (IL-31) to its receptor and subsequent signal transduction. Nemolizumab can used be in research of atopic dermatitis (AD). MW:145.5 KD. | ||
| A2631 | Anti-IL-3Ra / CD123 (SGN-CD123A) | Anti-IL-3Ra / CD123 (SGN-CD123A) is an antibody-drug conjugate targeting IL-3 alpha chain receptor (CD123). It is a potent antileukemic agent in treatment of acute myelogenous leukemia(AML). MW :146.14 KD. | ||
| A2665 | Anrukinzumab (Anti-IL-13) | Anrukinzumab (Anti-IL-13) is a humanized monoclonal antibody targeting IL-13. It reduces lung inflammation and can be used in studies of ulcerative colitis (UC) as well as asthma. MW :150 KD. | ||
| A2666 | Anti-IL-13Ra2 / CD213a2 | Anti-IL-13Ra2 / CD213a2 is a humanized monoclonal antibody targeting IL-13Ra2. It exhibits potentcy against malignant gliomas (MG), head and neck tumors, ovarian cancer and kidney cancer. MW :150 KD. | ||
| A2667 | Imsidolimab (Anti-IL-1RL2 / IL-36R) | Imsidolimab (Anti-IL-1RL2 / IL-36R) is a high-affinity, humanized monoclonal antibody targeting IL-36R. It has potential application in generalized pustular psoriasis (GPP) and other inflammatory skin diseases. MW :150 KD. | ||
| A2668 | Etokimab (Anti-IL-33) | Etokimab (Anti-IL-33) is a humanized monoclonal antibody that targets IL-33. It can be used for the research of atopic dermatitis. MW :146.56 KD. | ||
| A2669 | Lusvertikimab (Anti-IL-7Ra / CD127) | Lusvertikimab (Anti-IL-7Ra / CD127) is a humanized monoclonal antibody targeting IL7R. It has anti-leukemic efficacy and has the potential for B cell precursor acute lymphoblastic leukemia (BCP-ALL) research. MW :145.64 KD. | ||
| A2107 | Anti-mouse CD25 (IL-2Rα)-InVivo | The PC-61.5.3 monoclonal antibody reacts with mouse IL-2Rα also known as CD25, Ly-43, p55, or Tac.The PC-61.5.3 antibody has been shown to inhibit the binding of IL-2 to both the low and high affinity IL-2 receptor forms. Additionally, the PC-61.5.3 antibody is commonly used to deplete CD4+FoxP3+ T regulatory cells in vivo. |
-InVivo.gif)
|
|
| A2109 | Anti-mouse IL-4-InVivo | The 11B11 monoclonal antibody reacts with mouse IL-4 (interleukin-4) which is a multifunctional 14 kDa cytokine.The 11B11 monoclonal antibody has been shown to neutralize the bioactivity of natural or recombinant IL-4. | ||
| S1322 | Dexamethasone | Dexamethasone is a potent synthetic member of the glucocorticoid class of steroid drugs, and an interleukin receptor modulator that has anti-inflammatory and immunosuppressant effects. Dexamethasone induces autophagy and mitophagy. Dexamethasone is tested in hospitalized patients with COVID-19 and is found to have benefits for critically ill patients. |
|
|
| S3124 | Dexamethasone Acetate | Dexamethasone (NSC 39471,Dexamethasone 21-acetate) is a potent synthetic member of the glucocorticoid class of steroid drugs, and an interleukin receptor modulator that has anti-inflammatory and immunosuppressant effects. |
|
Choose Selective IL Receptor Inhibitors
Tags: IL Receptor inhibitor|IL Receptor agonist|IL Receptor activator|IL Receptor inducer|IL Receptor antagonist|IL Receptor signaling pathway|IL Receptor assay kit
Products are for research use only. Not for human use. We do not sell to patients.
©Copyright 2013 Selleck Chemicals. All Rights Reserved.